Baidu
map

Arch Gynecol Obstet:宫颈癌的预后因子--嗜神经侵袭(PNI)

2015-02-03 MedSci MedSci原创

最近发表的研究表明,嗜神经侵袭(PNI) 可能作为宫颈癌的不良预后因素之一。本文系统的分析了嗜神经侵袭(PNI)对宫颈癌的整体生存率和无病生存率 的影响。 我们基于PubMed和Cochrane clinical trials数据库搜索了截至2013年9月以前的相关研究文章。对宫颈癌根治术+淋巴结切除术后的嗜神经侵袭(PNI)影响的生存分析进行了回顾性研究。 在数据收集与分析中,研究人员基于

最近发表的研究表明,嗜神经侵袭(PNI) 可能作为宫颈癌的不良预后因素之一。本文系统的分析了嗜神经侵袭(PNI)对宫颈癌的整体生存率和无病生存率 的影响。

我们基于PubMed和Cochrane clinical trials数据库搜索了截至2013年9月以前的相关研究文章。对宫颈癌根治术+淋巴结切除术后的嗜神经侵袭(PNI)影响的生存分析进行了回顾性研究。

在数据收集与分析中,研究人员基于 Newcastle-Ottawa scale (NOS)评分单独对试验特征、结果以及质量评估的数据及结果提取,基于分析风险比(HR)对出现嗜神经侵袭的患者整体生存率和无病生存率的结果进行分析。

通过对这些研究的分析得出伴有嗜神经侵袭(PNI)子宫癌患者的整体生存率较低(HR 2.21, 95 % CI 1.36-3.59, P = 0.001。在PNI组,尽管无病生存率相对较低(HR 1.35, 95 % CI 0.78-2.31, P = 0.28), 但是结果并无统计学意义。

结论:在伴有嗜神经侵袭(PNI)子宫癌患者中,整体生存率较低。因此,我们可以得出在宫颈癌中PNI是一个不良预后的影响因子。基于这些研究结果,PNI应该是一个独立的子宫颈癌的预后因素,在术后我们应该进行一些相适应的辅助治疗。

原始出处

Cui L1, Shi Y, Zhang GN.Perineural invasion as a prognostic factor for cervical cancer: a systematic review and meta-analysis.Arch Gynecol Obstet. 2015 Jan 31

本文是MedSci原创,欢迎转载,转载请注明出处,非常感谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2011168, encodeId=95d0201116896, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Nov 01 15:15:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043830, encodeId=9d5420438304a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Aug 08 12:15:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910944, encodeId=1ba7191094466, content=<a href='/topic/show?id=1cad1001e728' target=_blank style='color:#2F92EE;'>#预后因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100177, encryptionId=1cad1001e728, topicName=预后因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 29 11:15:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407941, encodeId=5d99140e94156, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Thu Feb 05 01:15:00 CST 2015, time=2015-02-05, status=1, ipAttribution=)]
    2015-11-01 yhy100200
  2. [GetPortalCommentsPageByObjectIdResponse(id=2011168, encodeId=95d0201116896, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Nov 01 15:15:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043830, encodeId=9d5420438304a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Aug 08 12:15:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910944, encodeId=1ba7191094466, content=<a href='/topic/show?id=1cad1001e728' target=_blank style='color:#2F92EE;'>#预后因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100177, encryptionId=1cad1001e728, topicName=预后因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 29 11:15:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407941, encodeId=5d99140e94156, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Thu Feb 05 01:15:00 CST 2015, time=2015-02-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2011168, encodeId=95d0201116896, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Nov 01 15:15:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043830, encodeId=9d5420438304a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Aug 08 12:15:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910944, encodeId=1ba7191094466, content=<a href='/topic/show?id=1cad1001e728' target=_blank style='color:#2F92EE;'>#预后因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100177, encryptionId=1cad1001e728, topicName=预后因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 29 11:15:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407941, encodeId=5d99140e94156, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Thu Feb 05 01:15:00 CST 2015, time=2015-02-05, status=1, ipAttribution=)]
    2015-03-29 lqvr
  4. [GetPortalCommentsPageByObjectIdResponse(id=2011168, encodeId=95d0201116896, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Nov 01 15:15:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043830, encodeId=9d5420438304a, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Aug 08 12:15:00 CST 2015, time=2015-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910944, encodeId=1ba7191094466, content=<a href='/topic/show?id=1cad1001e728' target=_blank style='color:#2F92EE;'>#预后因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100177, encryptionId=1cad1001e728, topicName=预后因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Mar 29 11:15:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407941, encodeId=5d99140e94156, content=<a href='/topic/show?id=92194628826' target=_blank style='color:#2F92EE;'>#宫颈#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46288, encryptionId=92194628826, topicName=宫颈)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11102737131, createdName=一闲, createdTime=Thu Feb 05 01:15:00 CST 2015, time=2015-02-05, status=1, ipAttribution=)]
    2015-02-05 一闲

相关资讯

罗氏Avastin再获批 **用于晚期宫颈癌的生物药物

FDA通过优选审评程序批准罗氏阿瓦斯汀一项新适应症。 而就在三个月之前,FDA批准罗氏的这款药物用于宫颈癌,这次FDA是批准这款药物与化疗药物合并用于对铂类耐药的复发性卵巢癌。 此次批准基于该公司AURELIA研究数据,这项研究显示阿瓦斯汀在接受该药物与化疗药物合并治疗的妇女中使疾病恶化风险降低了62%。“阿瓦斯汀加化疗治疗是逾十五年来这种难以治疗卵巢癌妇女患者的首个新型治疗选择,”罗氏首

J Clin Pathol:HPV疫苗对预防宫颈癌效果显著

目前发现至少13种高危(HR)型人类乳头瘤病毒(HPV)与宫颈癌的发生有关。而且,高危型HPV几乎在所有宫颈癌中出现这一概念已被广泛认可。高危型HPV同时也在85%--95%的侵袭前高级别宫颈病变(定义为宫颈上皮内瘤变(CIN)2或3级)中出现。两种经过批准使用的预防性HPV疫苗包括了病毒样粒子,可以诱导机体针对HPV16和HPV18产生强烈的免疫反应,并且发挥出几乎100%的效用。HPV16和H

The Lancet Oncology:贝伐单抗有望用于治疗晚期宫颈癌

Bevacizumab(贝伐单抗)是重组的人源化单克隆抗体,是美国第一个获得批准上市的抑制肿瘤血管生成的药。Gynecologic Oncology Group protocol 240(GOG 240,妇科肿瘤研究组)是一项灵活的3期临床试验,旨在验证化疗联合贝伐单抗与单独给予化疗相比是否能够显著提高晚期宫颈癌患者的整体和无进展生存期,以及患者获得整体的客观肿瘤反应的比例。在本研究中,来自美国马

Nature Genetics:HPV全基因组整合图谱分析

来自华中科技大学、南方医科大学、华大基因研究院等机构的研究人员,通过对宫颈癌(cervical cancer)进行全基因组人类乳头瘤病毒(HPV)整合图谱分析,鉴别出了一些成簇的基因组热点,并揭示出了由微同源(microhomology)介导的一种潜在整合机制。这些研究结果发表在1月12日的《自然遗传学》(Nature Genetics)杂志上。 华中科技大学的马丁(Ding Ma)教授、汪辉(

宫颈癌患者保育门诊开诊

2014年12月2日,全国首个针对宫颈癌患者的保育门诊在上海复旦大学附属肿瘤医院开诊,首次即接诊50余人次。 宫颈癌发病正呈现出年轻化的趋势,35岁以下发病的女性比例已超过20%。年轻的宫颈癌患者中40%以上尚未婚或未育。过去将宫颈和子宫“一锅端”的手术方式,虽说能根治恶性肿瘤,但也意味着这批患者将终生失去生育机会。吴小华教授的团队在10年间共完成创新性根治性宫颈切除手术250余例,可在不影响疗

宫颈癌疫苗何时惠及中国女性

增长 研究分析发现,从2006年~2012年,宫颈癌疫苗在我国免疫接种已延期七年,若不施加筛查等其他有效干预措施,可能造成未来38万宫颈癌新发病例,而今后每推迟一年开展HPV疫苗免疫接种,可能造成5.5万人罹患宫颈癌,3万人死于宫颈癌,还会使很多女性感染人乳头瘤病毒,进而罹患相关疾病。 错失 HPV有一百多种类型,但超七成宫颈癌与16型和18型HPV病毒感染有关,中国女性HPV16型和H

Baidu
map
Baidu
map
Baidu
map